Skip to main content
    C

    Cullinan Oncology LLC (CGEM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.50
    -0.78 (-7.59%)

    Market Cap: $667.39M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cullinan Oncology LLC (CGEM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Cullinan Oncology LLC reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$219.88M, operating cash flow was -$175.75M and free cash flow was -$175.80M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$49.39M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $241.65M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$18.94MN/A100.0%-358.7%-356.3%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Dec 2015$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2016Dec 2015
    Revenue$0$0$0$0$18.94M$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$70.00K$43.00K$0$0
    Gross profit$0$0$0$0$18.94M$0-$70.00K-$43.00K$0$0
    Research and development$187.40M$142.90M$148.16M$91.95M$57.75M$43.21M$16.79M$9.58M$0$0
    Operating income-$241.65M-$196.92M-$191.09M$144.65M-$67.95M-$60.34M-$22.27M-$14.59M-$197.40K-$95.44K
    Net income-$219.88M-$167.57M-$155.10M$109.19M-$67.48M-$59.46M-$20.04M-$14.19M-$316.70K-$109.51K
    EBITDAN/AN/AN/A$146.09M-$67.91M-$60.04M-$22.20M-$14.54MN/AN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$79.00K$0$0$0-$77.00K$0$0$0-$77.00K
    Operating income-$52.60M-$57.25M-$53.70M-$55.26M-$55.59M-$75.80M-$55.00M-$55.05M-$48.85M-$50.03M-$42.99M-$45.48M
    Net income-$49.39M-$53.70M-$49.66M-$50.71M-$50.61M-$70.06M-$48.50M-$47.65M-$40.56M-$42.03M-$37.34M-$25.56M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $780.00K by $87.55M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2016Dec 2015
    Total assets$448.37M$621.82M$484.18M$561.12M$437.19M$214.71M$100.46M$34.64M$3.44K$118
    Current assets$386.76M$414.67M$480.19M$474.47M$296.56M$212.28M$100.09M$34.22M$3.44K$118
    Cash and equivalents$88.33M$83.00M$98.43M$156.15M$59.77M$168.20M$63.25M$33.83M$91$118
    Total liabilities$39.64M$31.50M$30.29M$26.09M$11.81M$14.39M$140.37M$55.29M$578.28K$1.24M
    Short-term debt$780.00K$1.30M$1.44M$1.60MN/AN/AN/AN/A$330.41K$1.09M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$330.41K$1.09M
    Shareholder equity$0$590.33M$453.70M$535.03M$424.97M$199.01M-$40.77M-$20.65M-$574.85K-$1.24M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$322.56M$363.79M$402.98M$448.37M$484.13M$520.33M$579.68M$621.82M$653.25M$681.22M$449.43M$484.18M
    Total liabilities$41.27M$42.03M$36.81M$39.64M$32.76M$28.18M$27.84M$31.50M$25.39M$25.00M$23.77M$30.29M
    Cash and equivalents$88.26M$78.64M$75.08M$88.33M$103.33M$72.82M$76.66M$83.00M$102.08M$115.02M$74.23M$98.43M
    Shareholder equity$0$0$0$408.73M$451.37M$492.15M$551.84M$590.33M$627.86M$656.22M$425.67M$453.70M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2016Dec 2015
    Operating cash flow-$175.75M-$145.30M-$134.28M-$126.66M-$43.43M-$29.77M-$20.90M-$13.55M-$228.91K-$24.03K
    Capital expenditures$49.00K$0$208.00K$1.13M$0$10.00K$20.00K$261.00K$0$0
    Free cash flow-$175.80M-$145.30M-$134.48M-$127.80M-$43.43M-$29.78M-$20.92M-$13.81M-$228.91K-$24.03K
    Dividends paid$0$4.45M$0$33.28M$0$1.21MN/AN/AN/AN/A
    Share repurchasesN/AN/AN/AN/AN/A$6.57MN/AN/AN/AN/A
    Investing cash flow$179.99M-$136.31M$35.81M$248.97M-$333.77M-$5.42M-$35.40M-$261.00KN/AN/A
    Financing cash flow$1.09M$266.19M$40.75M-$25.93M$268.78M$140.14M$85.72M-$29.00K$228.88K$21.98K
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$43.08M-$38.22M-$46.05M-$38.11M-$36.88M-$57.61M-$43.16M-$36.63M-$34.14M-$36.29M-$38.25M-$18.13M
    Capital expendituresN/AN/A$0$11.00K$36.88M$0$0$0$0$0$0$0
    Free cash flowN/AN/A-$46.05M-$38.12M-$73.75M-$57.61M-$43.16M-$36.63M-$34.14M-$36.29M-$38.25M-$18.13M
    Last 12 quarters

    Frequently Asked Questions About CGEM

    What is Cullinan Oncology LLC's annual revenue?

    Cullinan Oncology LLC reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cullinan Oncology LLC profitable?

    No. Cullinan Oncology LLC reported net income of -$219.88M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CGEM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$175.75M minus capital expenditures of $49.00K produced free cash flow of -$175.80M.

    How much debt does Cullinan Oncology LLC have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $780.00K and cash and equivalents of $88.33M.